EUROPEAN JOURNAL OF NEUROLOGY, published by WILEY, stands as a leading platform for the dissemination of innovative research and clinical developments in the field of neurology. With a robust impact factor and prestigious rankings, including being positioned as Q1 in both Neurology and Clinical Neurology categories, the journal plays a pivotal role in shaping neurological sciences from 1994 to 2024. Its Scopus rank highlights its importance, being in the 88th percentile for clinical neurology and 87th percentile for neuroscience. Located in the United Kingdom, the journal thrives as a vital resource for researchers, clinicians, and students dedicated to improving neurological health outcomes. Although it does not offer Open Access, its subscription-based model ensures high-quality peer-reviewed articles are accessible to a global audience, reflecting the continuous pursuit of excellence in neurological research and patient care.

Neurology International is a prestigious open-access journal published by MDPI that has been making significant contributions to the field of neurology since its establishment in 2009. With its ISSN 2035-8377, this journal is committed to disseminating high-quality, peer-reviewed research that addresses a wide range of clinical topics in neurology. Operating out of Basel, Switzerland, the journal holds a respectable Q2 ranking in the clinical neurology category as of 2023, indicating its influence and dedication to advancing scientific knowledge. Researchers and practitioners alike will find value in its comprehensive articles, which are readily accessible to a global audience, facilitating the sharing of innovative findings and clinical practices. As it converges towards 2024, Neurology International continues to provide a vital platform for scholarly discourse, aiming to improve patient outcomes and enhance our understanding of neurological disorders.

NEUROLOGIST, an esteemed journal published by Lippincott Williams & Wilkins, serves as a vital resource in the fields of Neurology and Medicine. With an ISSN of 1074-7931 and an E-ISSN of 2331-2637, this journal has been dedicated to advancing the understanding of neurological disorders since its inception in 1996, with continual contributions through 2024. Achieving a respectable Q3 rank in both Medicine (miscellaneous) and Neurology (clinical), it provides an essential platform for disseminating innovative research and clinical studies. Although it is not an open-access publication, NEUROLOGIST promotes a rich exchange of ideas and findings for researchers, healthcare professionals, and students alike, helping to bridge the gaps in neurological research and practice. The journal is recognized for its commitment to enhancing clinical practice and research methodology, making it a valuable asset for anyone engaged in the dynamic field of neurology.

Annals of Indian Academy of Neurology is a premier open access journal dedicated to advancing the field of Neurology, serving as a vital resource for researchers, healthcare professionals, and students since its inception in 2006. Published by the esteemed Wolters Kluwer Medknow Publications, this journal has established itself within the academic community, boasting a Q3 quartile ranking in clinical neurology according to the 2023 category quartiles and a Scopus rank placing it in the 35th percentile among 400 comparable journals. With a focus on clinical advancements and research innovations in neurology, the journal aims to disseminate high-quality and impactful studies that address the complex challenges faced in the neurological landscape, particularly within the Indian context. The open access model ensures that the latest research is readily accessible to a global audience, thereby promoting collaboration and knowledge sharing within the neurosciences.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

Canadian Journal of Neurological Sciences, published by Cambridge University Press, stands as a reputable source of knowledge in the field of neurology, dedicated to advancing research and clinical practice. With an ISSN of 0317-1671 and an E-ISSN of 2057-0155, this journal has been a cornerstone for the exchange of ideas since its inception in 1974 and will continue to cater to the academic community until 2024. Recognized in the top quartile (Q2) in various categories including Medicine (miscellaneous) and Neurology (clinical), its articles engage a broad audience, ranging from established researchers to students seeking to deepen their understanding of neurological sciences. Although the journal is not an open-access publication, it provides vital insights and research findings that contribute significantly to its fields. With a Scopus rank of #183 in clinical neurology and a percentile ranking that reflects its commendable standing, the Canadian Journal of Neurological Sciences is indispensable for those committed to the exploration and treatment of neurological disorders.

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

European Neurology, published by KARGER, is a distinguished journal in the field of neurology, catering to both clinical and neuroscience specialties. Since its inception in 1897 and continuing through 2024, the journal has been a vital platform for disseminating significant research findings and insights in neurology. With an ISSN of 0014-3022 and E-ISSN of 1421-9913, it ranks in the Q3 quartile in both clinical neurology and general neurology categories, reflecting its commitment to scholarly excellence while holding the 175th rank in clinical medicine and the 93rd in neuroscience, according to Scopus metrics. European Neurology facilitates a deeper understanding of neurological disorders and treatments, appealing to a diverse readership that includes researchers, clinicians, and students alike. Despite not currently offering open access, the journal’s rigorous peer-review process ensures that only high-quality research reaches its audience, making it an essential resource for those looking to stay informed in the rapidly evolving field of neurology.

METABOLIC BRAIN DISEASE, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal dedicated to advancing our understanding of the metabolic processes impacting brain health and disease. Established in 1986 and set to continue until 2024, this journal encompasses a wide range of interdisciplinary research that intersects the fields of Biochemistry, Cellular and Molecular Neuroscience, and Neurology, as evidenced by its notable quartile placements in Q2 and Q3 for 2023. With an ISSN of 0885-7490 and an E-ISSN of 1573-7365, it serves as a vital resource for researchers and practitioners aiming to deepen their insights into cerebral metabolic disorders and their implications. Although currently not an Open Access option, its rigorous peer-review process ensures that high-quality, impactful research reaches its audience. Showcasing a significant rank within the top percentile of its categories, METABOLIC BRAIN DISEASE is instrumental in shaping the future of neurological research and clinical applications.